Angelo Porciuncula
Associate Research ScientistCards
About
Research
Publications
2026
Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer
Lopez-Janeiro A, González-Gomariz J, Issa F, Hester J, Porciuncula A, Teijeira A, Luri-Rey C, Ruiz-Guillamon D, Perez-Gracia J, Perez-Ruiz E, Barragan I, Martín-Algarra S, Sanmamed M, Ortego I, Rodriguez-Ruiz M, Alexandru R, Rodriguez I, Arrieta-Aranzueque S, Rimm D, Aung T, Schalper K, de Andrea C, Melero I. Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer. Journal Of Clinical Investigation 2026, 136: e200987. PMID: 42065248, PMCID: PMC13132367, DOI: 10.1172/jci200987.Peer-Reviewed Original ResearchConceptsNon-small-cell lung cancerCD8+ T cellsCytotoxic T lymphocytesCheckpoint inhibitorsT cellsCD8+ T cell infiltrationConventional type 1 dendritic cellsContext of costimulatory moleculesType 1 dendritic cellsTissue immunofluorescenceCancer typesT lymphocyte densityCheckpoint inhibitor responseT cell infiltrationT cell activationT cell transcriptsAntigens to CD8Multiple cancer typesCostimulatory moleculesUrothelial cancerDendritic cellsFlt3-LCCL5 chemokinesClinical benefitT lymphocytes
2025
Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Appleman V, Matsuda A, Ganno M, Zhang D, Rosentrater E, Lopez A, Porciuncula A, Hatten T, Christensen C, Merrigan S, Lee H, Lee M, Wang C, Dong L, Huang J, Iartchouk N, Wang J, Xu H, Yoneyama T, Piatkov K, Haridas S, Harbison C, Gregory R, Parent A, Lineberry N, Arendt C, Schalper K, Abu-Yousif A. Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500. Cancer Immunology Research 2025, 13: 661-679. PMID: 39918395, PMCID: PMC12046323, DOI: 10.1158/2326-6066.cir-24-0103.Peer-Reviewed Original ResearchIntratumoral myeloid cellsMyeloid cellsTumor microenvironmentImmune responseCCR2+ cellsI interferonImmunosuppressive myeloid populationsImmune activation in vitroImmune cell markersLocal immune activationMurine tumor modelsAdaptive immune responsesAntibody drug conjugatesType I interferonAntitumor immunityInnate immune responseMyeloid populationsSTING agonistsSolid tumorsCCR2 proteinImmune activationTumor modelCell markersHuman tumorsAdaptive immunity